COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

• In Q1 following a development achievement, CollPlant received a $2 million payment from AbbVie – Collaboration Updates AbbVie Collaboration In February 2025, following a key development milestone, CollPlant received a$2 million milestone payment from its partner, AbbVie, pursuant to the existing development and commercialization agreement. Under this agreement, CollPlant granted AbbVie a worldwide exclusive license to use its recombinant human collagen (rhCollagen) technology in combination with AbbVie's ...